A phase I trial of the pharmacokinetics, toxicity, and activity of KNI-272, an inhibitor of HIV-1 protease, in patients with AIDS or symptomatic HIV infection

Antiviral Research

Volumn 41, Issue 1, 1999, Pages 21-33

  Humphrey, Rachel W ^a   Wyvill, Kathleen M ^a   Nguyen, Bach Yen ^a   Shay, Laura E ^a   Kohler, David R ^b   Steinberg, Seth M ^a   Ueno, Takamasa ^c   Fukasawa, Tominaga ^c   Shintani, Makoto ^c   Hayashi, Hideya ^c   Mitsuya, Hiroaki ^a   Yarchoan, Robert ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c JAPAN ENERGY CORPORATION   (Japan)

Author keywords

AIDS; HIV; HIV 1 protease; KNI 272; Protease inhibitor

Indexed keywords

AMINOTRANSFERASE; KYNOSTATIN 272; PROTEINASE; PROTEINASE INHIBITOR;

ABDOMINAL PAIN; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG ACTIVITY; DRUG BIOAVAILABILITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGLYCEMIA; HYPOGLYCEMIA; INTRAVENOUS DRUG ADMINISTRATION; LIVER DYSFUNCTION; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SORE THROAT;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; RNA, VIRAL;

EID: 0033082815     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(98)00058-8     Document Type: Article

References (36)

1. Anonymous, 1994. WHO case definitions for AIDS surveillance in adults and adolescents. Update: Trends in AIDS diagnosis and reporting under the expanded surveillance definition for adolescents and adults - United States, 1993. Wkly Epidemiol. Rec. 69, 273-275.
2. Carr, A., Samaras, K., Chisholm, D.J., Cooper, D.A., 1998. Pathogenesis of HIV-1-protease inhibitor- associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 351, 1881-1883.
3. Chokekijchai, S, Shirasaka, T, Weinstein, J.N., Mitsuya, H., 1995. In vitro anti-HIV-1 activity of HIV protease inhibitor KNI-272 in resting and activated cells: Implications for its combined use with AZT or ddI. Antiviral Res. 28, 25-38.
4. Condra, J.H., Schleif, W.A., Blahy, O.M., et al., 1995. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374, 569-571.
5. Condra, J.H., Holder, D.J., Schleif, W.A. et al., 1996. Bi-directional inhibition of HIV-1 drug resistance selection by combination therapy with indinavir and reverse transcriptase inhibitors. XI International Conference on AIDS, Vancouver, July 7-12, 1996. Supplement.
6. Danner, S.A., Carr, A., Leonard, J.M., et al., 1995. A shortterm study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European- Australian Collaborative Ritonavir Study Group. New Engl. J. Med. 333, 1528-1533.
7. Deeks, S.G., Smith, M., Holodniy, M., Kahn, J.O., 1997. HIV-1 protease inhibitors-a review for clinicians. J. Am. Med. Assoc. 277, 145-153.
8. Dreyer, G., Metcalf, B., Tomaszek, T., et al., 1989. Inhibition of human immunodeficiency virus 1 protease in vitro: Rational design of substrate analogue inhibitors. Proc. Natl. Acad. Sci. USA 86, 9752-9756.
9. 2 symmetric inhibitor complexed to HIV-1 protease. Science 249, 527- 533.
10. Fischl, M.A., Richman, D.D., Flexner, C., et al., 1997. phase I/II study of the toxicity, pharmacokinetics, and activity of the HIV protease inhibitor SC-52151. J. Acq. Immune Defic. Syndr. Hum. Retrovirol. 15, 28-34.
11. Ginsburg, C., Salmon-Ceron, S., Vassilief, D., et al., 1997. Unusual occurrence of spontaneous haematomas in three asymptomatic HIV-infected haemophilia patients a few days after the onset of ritonavir treatment. AIDS 11, 388-389.
12. Gulnik, S.V., Suvorov, L.I., Liu, B., et al., 1995. Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry 34, 9282-9287.
13. Hirsch, M.S., Conway, B., D'Aquila, R.T., et al., 1998. Antiretroviral drug resistance testing in adults with HIV infection: Implications for clinical management. International AIDS Society - USA Panel [see comments]. J. Am. Med. Assoc. 279, 1984-1991.
14. Hsu, A., Granneman, G.R., Cao, G., et al., 1998. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir. Clin. Pharmacol. Ther. 63, 453-464.
15. Humphrey, R., Ohagen, A., Davis, D., et al., 1997. Reversal of human immunodeficiency virus type 1 (HIV-1) protease inhibition in isolated virions does not restore particle infectivity. Antimicrob. Agents Chemother. 41, 1017-1023.
16. Kageyama, S., Mimoto, T., Murakawa, Y., et al., 1993. In vitro anti-human immunodeficiency virus (HIV) activities of transition state mimetic HIV protease inhibitors containing allophenylnorstatine. Antimicrob. Agents Chemother. 37, 810-817.
17. Kageyama, S., Anderson, B., Hoesterey, B., et al., 1994. Protein binding of human immunodeficiency virus protease inhibitor KNI-272 and alteration of its in vitro antiretroviral activity in the presence of high concentrations of proteins. Antimicrob. Agents Chemother. 38, 1107-1111.
18. Kempf, D., Norbeck, D., Codacovi, L., 1990. Structure-based C2 symmetric inhibitors of HIV protease. J. Med. Chem. 33, 2687-2689.
19. Kiriyama, A., Mimoto, T., Kisanuki, S., Kiso, Y., Takada, K., 1993. Comparison of a new orally potent tripeptide HIV-1 protease inhibitor (anti-AIDS drug) based on pharmacokinetic characteristics in rats after intravenous and intraduodenal administrations. Biopharm. Drug Dispos. 14, 697-707.
20. Kiriyama, A., Fujita, K., Takemura, S., Kuramoto, H., Kiso, Y., Takada, K., 1994. Plasma pharmacokinetics and urinary and biliary excretion of a new potent tripeptide HIV-1 protease inhibitor, KNI-272, in rats after intravenous administration. Biopharm. Drug Dispos. 15, 617- 626.
21. Lorenzi, P., Yerly, S., Abderrakim, K., et al., 1997. Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir. Swiss HIV Cohort Study. AIDS 11, F95-F99.
22. Markowitz, M., Saag, M., Powderly, W.G., et al., 1995. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. New Engl. J. Med. 333, 1534-1539.
23. McQuade, T.J., Tomasselli, A.G., Liu, L., et al., 1990. A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation. Science 247, 454-456.
24. Mellors, J.W., Rinaldo, C.R. Jr., Gupta, P., White, R.M., Todd, J.A., Kingsley, L.A., 1996. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272, 1167-1170.
25. Mimoto, T., Imai, J., Kisanuki, S., et al., 1992. Kynostantin (KNI)-227 and -272, highly potent anti-HIV agents: Conformationally constrained tripeptide inhibitors of HIV protease containing allophenylnorstatine. Chem. Pharm. Bull. 40, 2251-2253.
26. Molla, A., Korneyeva, M., Kempf, D., 1996. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat. Med. 2, 760-766.
27. Mueller, B.U., Anderson, B.D., Farley, M.Q., et al., 1998. Pharmacokinetics of the protease inhibitor KNI-272 in plasma and cerebrospinal fluid in nonhuman primates after intravenous dosing and in human immunodeficiency virus-infected children after intravenous and oral dosing [in process citation]. Antimicrob. Agents Chemother. 42, 1815-1818.
28. Patick, A., Mo, H., Markowitz, M., et al., 1996. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. AnTimicrob. Agents Chemother. 40, 292-297.
29. Ridky, T., Leis, J., 1995. Development of drug resistance to HIV-1 protease inhibitors. J. Biol. Chem. 270, 29621- 29623.
30. Roberts, N.A., Martin, J.A., Kinchington, D., et al., 1990. Rational design of peptide-based HIV proteinase inhibitors. Science 248, 358-361.
31. Schapiro, J.M., Winters, M.A., Stewart, F., et al., 1996. The effect of high-dose saquinavir on viral load and CD4 + T-cell counts in HIV-infected patients. Ann. Intern. Med. 124, 1039-1050.
32. Stein, D., Fish, D., Bilello, J., Preston, S., Martineau, G., Drusano, G., 1996. A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS 10, 485-492.
33. Tisdale, M., Myers, R., Maschera, B., 1995. Cross-resistance analysis of HIV-1 variants individually selected for resistance to five different protease inhibitors. Antimicrob. Agents Chemother. 39, 1704-1710.
34. 3. Fourth Conference on Retroviruses and Opportunistic Infections, Washington, DC, Jan 22-26, 1997.
35. Wittes, R.E., 1991. Common toxicity criteria for cancer clinical trials. In: Wittes, R.E. (Ed.), Manual of Oncologic TheraPeutics. J.B. Lippencott, Philadelphia, PA, pp. 445-448.
36. Yamada, A., Anderson, B., Kageyama, S. et al., 1996. Detection of mutations conferring on HIV-1 drug resistance in patients receiving KNI-272. XI International Int. Conf. on AIDS, Vancouver, July 7-12, 1996. Vol. 11, p. 310 (abstract no. Th.B.4346).